3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
182
Magnetic Resonance Spectroscopy
163
Specimen Handling
135
enzalutamide
126
Nivolumab
124
Gemcitabine
99
Docetaxel
96
Radiosurgery
92
Prednisone
85
Androgen Antagonists
82
Abiraterone Acetate
81
Radiotherapy
75
apalutamide
68
Cisplatin
65
darolutamide
63
Ipilimumab
63
Biopsy
60
abiraterone
58
Carboplatin
56
cabozantinib
55
Leuprolide
53
enfortumab vedotin
49
Radiation
48
Pluvicto
45
Standard of Care
44
atezolizumab
40
Surveys and Questionnaires
39
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
37
X-Rays
37
avelumab
35
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
gadoterate meglumine
×
Genitourinary
×
1 year
×
Clear all
NCT04373564
2026-01-22
ODYSSEY
Guerbet
Phase 4
Recruiting
2,076 enrolled